RxSight, Inc. Cash Flow Statement
RXST|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
RxSight, Inc. used $42M in operating cash flow and negative free cash flow of $46M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 3.59 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$48.6M | -$66.8M | -$66.8M | -$48.7M | $27.6M |
| Depreciation & Amortization | $4.1M | $3.9M | $3.9M | $4.0M | $3.9M |
| Operating Cash Flow | -$41.6M | -$58.9M | -$58.9M | -$44.7M | -$35.2M |
| Capital Expenditures | $4.8M | $2.4M | $2.4M | $1.9M | $2.5M |
| Free Cash Flow | -$46.4M | -$61.2M | -$61.2M | -$46.6M | -$37.7M |
| FCF Margin | -52.1% | -125.0% | -125.0% | -206.5% | -257.1% |